Abstract 370P
Background
Immune checkpoint inhibitors (ICI) have proven efficacy in R/M HNSCC. In LMICs, <5% of patients have access to ICI at approved doses. We assessed the efficacy of low dose ICI in locally advanced/inoperable HNSCC.
Methods
We conducted retrospective analysis of patients with locally advanced/inoperable HNSCC who underwent induction chemotherapy with low dose nivolumab. Eligible doses of nivolumab were <3mg/kg q2w with chemotherapy backbone of TPX or TP+/- OMCT. The principal outcomes were conversion to radical therapy, ORR, PFS and OS.
Results
We included 111 patients, 78.4% males with median age 48. Primary sites- oral cavity(71.2%), hypopharynx(11.7%), oropharynx(9%) and larynx(8.1%) mainly stage IVA/IVB. TPX/TP was used in 95.4%. Nivolumab 20/40/100 mg all 2/3/4 weeks were the doses and intervals. The harmonized median dose of nivolumab was 0.51 mg/kg q2w (median 3 doses). Response assessment was available for 92 of 111 patients- CR in 7 (6.3%), PR in 65(58.6%), SD in 12(10.8%), PD in 8(7.2%). ORR was 78.2% in those assessed. 25(31.6%) oral cavity tumours became resectable following induction, of whom, 8(32%) had pCR. 60% of oropharyngeal, 69% of hypopharynx and 77.8% of larynx primary site underwent radical RT/CRT after induction. Median PFS is 18.6 months. PFS and OS at 1 year were 64.6% and 82.6%. Median PFS not reached in the cohort with pCR/rCR and 18 months in the group without(p 0.03). No recurrence/death observed thus far in those with pCR. At nivolumab doses <0.6mg/kg, median PFS was significantly lower (13 months vs NR; p 0.04). The retrospective design introduces potential confounders. Grade 3/4 AEs were neutropenia (14.4%), CINV (2.7%), anemia(2.7%), mucositis(1.8%) and febrile neutropenia(1%); Any grade hyponatremia(14%), hypothyroidism(5%).
Conclusions
Low-dose ICI with induction chemotherapy demonstrated promising ORR and conversion to radical therapy. Survival, although immature, appears favourable, especially for patients with pCR/rCR. Doses of nivolumab < 0.6mg/kg may compromise survival. Low-dose (1/6th of standard dose) regimens could enhance ICI access in LMICs due to significantly reduced costs and merit investigation in randomised trials to confirm our findings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Institutional Review Board (Ethics committee) of the Christian Medical College Vellor.
Funding
Has not received any fundin.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract